---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-24-000024"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:03:01.397349+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals Q4 revenue up 39.7% YoY; issues 2024 guidance with Cortrophin Gel growth 52-61%

## Summary
- Q4 net revenues $131.7M (+39.7% YoY); GAAP diluted EPS $0.04; adjusted non-GAAP diluted EPS $1.00.
- Rare Disease (Cortrophin Gel) Q4 revenue $41.7M (+137.3% YoY) with record new patient starts and prescribers.
- Full-year 2023 net revenue $486.8M, adjusted EBITDA $133.8M, operating cash flow $119.0M.
- 2024 guidance: net revenue $520-542M, Cortrophin Gel $170-180M, adjusted EBITDA $135-145M, adjusted EPS $4.26-$4.67.
- Generics segment revenue $71.8M (+23.8% YoY); 11 new products launched in 2023.

## SEC filing metadata
- accession: 0001023024-24-000024
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/0001023024-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/ani-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-24-000024
- JSON: https://secwatch.observer/filing/0001023024-24-000024.json
- Plain text: https://secwatch.observer/filing/0001023024-24-000024.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $131.7 million, net income $0.7 million, EPS $0.04. Guidance initiated.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $131.7 million
  - Net income: $0.7 million
  - EPS: $0.04
  - Guidance: initiated
  - Result: reported results
  source text: ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance • Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302424000024/0001023024-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.